PUBLISHER: The Business Research Company | PRODUCT CODE: 1948213
PUBLISHER: The Business Research Company | PRODUCT CODE: 1948213
Small animal imaging (in vivo) pertains to advanced imaging techniques designed for monitoring cellular activity, pharmacological effects, and disease progression in live animals. It enables the observation, definition, and quantification of normal and pathologic processes in living animal organs and tissues in a non-invasive manner.
Key components of small animal imaging (in vivo) include micro-MRI, optical imaging, nuclear imaging, and other elements. Micro-MRI, a non-invasive technique, produces detailed three-dimensional (3D) images of tissues without exposing the subject to harmful radiation. This approach finds various applications, such as monitoring treatment response, assessing biodistribution, determining drug/target engagement, detecting cancer cells, exploring biomarkers, conducting longitudinal studies, and investigating epigenetics. These applications are employed in veterinary clinics, veterinary hospitals, as well as veterinary institutes and research centers.
Tariffs are influencing the small animal imaging (in-vivo) market by increasing costs of imported imaging detectors, scanners, contrast agents, electronic components, and precision optics. Research institutions and pharmaceutical laboratories in North America and Europe are most affected due to reliance on advanced imported imaging systems, while Asia-Pacific faces cost pressures on system procurement. These tariffs are increasing capital investment requirements and delaying equipment upgrades. At the same time, they are supporting regional manufacturing partnerships, localized system assembly, and domestic innovation in preclinical imaging technologies.
The small animal imaging (in-vivo) market research report is one of a series of new reports from The Business Research Company that provides small animal imaging (in-vivo) market statistics, including small animal imaging (in-vivo) industry global market size, regional shares, competitors with a small animal imaging (in-vivo) market share, detailed small animal imaging (in-vivo) market segments, market trends and opportunities, and any further data you may need to thrive in the small animal imaging (in-vivo) industry. This small animal imaging (in-vivo) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The small animal imaging (in-vivo) market size has grown rapidly in recent years. It will grow from $3.15 billion in 2025 to $3.54 billion in 2026 at a compound annual growth rate (CAGR) of 12.4%. The growth in the historic period can be attributed to growth in preclinical research activities, increasing drug discovery investments, expansion of academic research funding, rising use of animal models in disease studies, availability of advanced imaging modalities.
The small animal imaging (in-vivo) market size is expected to see rapid growth in the next few years. It will grow to $5.53 billion in 2030 at a compound annual growth rate (CAGR) of 11.8%. The growth in the forecast period can be attributed to increasing demand for precision medicine research tools, rising investments in translational research, expansion of oncology and neurological studies, growing adoption of ai-assisted diagnostics, increasing focus on real-time biological imaging. Major trends in the forecast period include increasing adoption of multimodal imaging systems, rising use of non-invasive in vivo imaging techniques, growing integration of ai-based image analysis, expansion of longitudinal disease monitoring studies, enhanced focus on high-resolution imaging capabilities.
Increasing healthcare sector spending is anticipated to support the expansion of the small animal imaging (in vivo) market in the coming years. Healthcare expenditure represents the total spending on health services, including both public and private outlays, expressed as a share of gross domestic product. Higher healthcare spending, along with growing awareness of health management, is promoting the adoption of self-care and advanced diagnostic approaches, where positron emission tomography systems are applied in methods such as small animal imaging. In vivo small animal imaging benefits the healthcare ecosystem by enabling noninvasive, real-time visualization of biological processes, accelerating drug discovery timelines, enhancing disease understanding, and supporting the development of more effective therapeutic solutions. For example, in May 2024, a report released by the Office for National Statistics, a United Kingdom-based government statistical authority, indicated that healthcare expenditure in the United Kingdom rose by 5.6% in nominal terms in 2023, while long-term health and social care spending increased by 2.8% in real terms in 2022. As a result, rising healthcare expenditure is contributing to the growth of the small animal imaging (in vivo) market.
Leading companies operating in the small animal imaging (in vivo) space are increasingly emphasizing advanced imaging software solutions, including real-time kinetic analysis capabilities, to address the growing demand for highly accurate, quantitative, and high-throughput preclinical research in areas such as oncology and neuroscience. These software solutions enable continuous acquisition and automated evaluation of dynamic bioluminescent signals over time, moving beyond conventional static single-timepoint imaging and generating more comprehensive kinetic profiles, improved reproducibility, and enhanced detection of peak signal phases. For instance, in April 2024, Spectral Instruments Imaging, a United States-based provider of preclinical imaging technologies, introduced Aura 4.5, the newest release of its in vivo imaging software. Aura 4.5 features a Kinetics mode that supports automated, real-time capture of bioluminescent signals across their entire temporal progression, including rise, plateau, and decay phases. The platform automatically determines and reports peak signal intensity, enabling researchers to achieve greater sensitivity and biological precision. In addition, the update simplifies data collection and minimizes manual handling, improving operational efficiency for longitudinal and time-critical studies such as pharmacokinetic analyses, gene expression research, and infection models.
In February 2024, Bruker Corporation, a US-based biotechnology research company, acquired Spectral Instruments Imaging for an undisclosed sum. This acquisition is intended to bolster Bruker Corporation's imaging technology capabilities, particularly in advanced imaging systems for life sciences and materials research. The integration of Spectral Instruments Imaging's expertise in specialized imaging solutions will enhance Bruker's offerings in this area. Spectral Instruments Imaging is a US-based company known for its advanced imaging solutions.
Major companies operating in the small animal imaging (in-vivo) market are Bruker Corporation, PerkinElmer Inc., Mediso Ltd., Aspect Imaging Ltd., Spectral Instruments Imaging LLC, Bioscan Inc., Gamma Medica-Ideas Inc., LI-COR Biosciences, Scanco Medical AG, TriFoil Imaging Inc., MR Solutions Ltd., MILabs B.V., Trifoil Imaging Inc., VisualSonics Inc., Fujifilm VisualSonics Inc., Sedecal S.A., Kubtec Medical Imaging, Carestream Health Inc., Thermo Fisher Scientific Inc., Rigaku Corporation
North America was the largest region in the small animal imaging (in-vivo) market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the small animal imaging (in-vivo) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the small animal imaging (in-vivo) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The small animal imaging (in-vivo) market includes revenues earned by PET, X-ray CT, MRI, and SPECT scanners. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Small Animal Imaging (In-Vivo) Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses small animal imaging (in-vivo) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for small animal imaging (in-vivo) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The small animal imaging (in-vivo) market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.